Document Type
Article
Publication Date
2003
Abstract
This article presents a piece of a larger, ongoing project on the phenomenon of market-driven manufacturing (MDM) and how tort law should address it. In contrast to the larger project, this article provides a relatively brief overview of the general phenomenon of MDM, but zeros in on how pharmaceutical manufacturers specifically practice MDM. MDM is a well-documented, much practiced activity, although American courts do not recognize MDM as a discrete category of conduct. The basic idea of MDM is that marketing considerations should continuously control every aspect and stage of a product's lifecycle. When a company engages in MDM, it completely inverts the conception of product design, development, and dissemination that seems natural to those unfamiliar with modern producer practices.
Publication Citation
42 Washburn L.J. 575-599 (2003)
Scholarly Commons Citation
Feldman, Heidi Li, "Pushing Drugs: Genomics and Genetics, the Pharmaceutical Industry, and the Law of Negligence" (2003). Georgetown Law Faculty Publications and Other Works. 512.
https://scholarship.law.georgetown.edu/facpub/512